Skip to main content

Table 3 Selected trials of alemtuzumab monotherapy and chemoimmunotherapy in CLL patients

From: Therapeutic advancement of chronic lymphocytic leukemia

Reference (year)

Regimen

Phase

Number of patients

Treatment status

CR,%

ORR,%

Median PFS (months)

Median OS (months)

Hillmen, 2007 [25]

Alemtuzumab

3

149

Untreated

24

83

14.6

NR

 

Chlorambucil

 

148

Untreated

2

55

11.7

NR

Gritti, 2012 [27]

Alemtuzumab

2

18

F-ref

8

44

10.3

29.1

Stilgenbauer, 2011 [28]

AD

2

30

Untreated, del(17p)

20

97

16.9

>24 , NR

  

17

Relapse, del(17p)

0

76

10.4

15

  

40

F-ref

5

70

8.4

12

Geisler, 2011 [29]

AFC

3

129

Untreated, high-risk

57

88

37

NR

 

FC

 

133

Untreated, high-risk

45

80

31

NR

Badoux, 2011 [30]

CFAR

2

80

Refractory /relapse

29

65

10.6

N/A

Zent, 2011 [31]

PAR

2

19

Refractory /relapse

32

74

7

23

  1. Abbreviations: A, alemtuzumab; AD, alemtuzumab and dexamethasone; AFC, alemtuzumab plus fludarabine and cyclophosphamide; CFAR, fludarabine, cyclophosphamide, alemtuzumab and rituximab; CR, complete response; FC, fludarabine and cyclophosphamide; F-ref, fludarabine-refractory; N/A, not applicable; NR, not researched; Not Rep, not reported; ORR, overall response rate; OS, overall survival; PAR, pentostatin, alemtuzumab, and rituximab.